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Letters e97course controlled by a slow taper of prednisone
with onset of symptoms around the time of her
CD diagnosis. As in our patient, cPAN is generally
responsive to corticosteroids.3,4 Nonsteroidal
anti-inflammatory medications may be useful for
prevention and treatment of mild flares and were
successfully employed in our patient.
We present an instructive case of cPAN pre-
senting as a solitary blue toe to make clinicians
aware of this unusual presentation in order to
facilitate initiation of appropriate work-up and
therapy.
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Major response to vemurafenib in patient with
severe cutaneous Langerhans cell histiocytosis
harboring BRAF V600E mutation
To the Editor: We report the case of a female patient
in her 90s with a history of age-related macular
degeneration and pulmonary embolism. In 2011, she
presented with pruritic, erythematous, confluent,
maculopapular skin lesions located on the trunk,
inframammary fold, groin, and genital and perianal
areas. Histology of a skin biopsy revealed a mono-
nuclear cell infiltrate that was morphologically and
phenotypically consistent with Langerhans cellOpen access under CC BY-NChistiocytosis (LCH) expressing CD1a and S100-
protein by immunohistochemistry. A body
computed tomography scan showed no visceral
involvement, the patient had no exophthalmos or
diabetes insipidus, and laboratory tests related to
LCH secondary localizations were normal (eg, in-
flammatory and hepatic markers, hemogram).
Subsequently, a diagnosis of single system cuta-
neous LCH was established.
Topical and systemic corticosteroid treatments
failed to elicit any clinical improvement as first-line
treatment, and the patient was suffering from chronic
and severe pruritus and pain, affecting her quality of
life that declined significantly. A second line of
systemic treatment with thalidomide was initiated
but was quickly discontinued because the patient
experienced minor clinical response with major side
effects such as dizziness, asthenia, and impaired
coordination.
Recently, she experienced a severe new flare of
her disease with multiple papulonodular lesions in
the same skin areas (Fig 1, before). The patient
complained of major pain and had suicidal ideation
related to her intolerable skin discomfort. No ex-
tracutaneous involvement was found, and a new
biopsy confirmed the diagnosis of widespread single
system cutaneous LCH (Fig 2, A-C). In conjunction
with this finding, the DNA from the biopsy was
extracted and a pyrosequencing analysis revealed a
BRAF V600E mutation, as expected for up to 57% of
LCH cases.1
After a multidisciplinary consultation, she was
started on a third-line vemurafenib treatment, (960
mg orally twice a day) immediately after obtaining
written informed consent.
Vemurafenib induced a major clinical improve-
ment in the first days of treatment. The patient was
seen for follow-up 3 weeks after vemurafenib
introduction and showed indisputable regression of
her cutaneous lesions. Moreover, histopathologic
and immunohistochemical studies confirmed the
clinical response, in that a new biopsy revealed the
absence of remaining cells expressing LCH markers
(Fig 2, D and E). After the third month of treatment,
the clinical response remained stable and after 6
months of vemurafenib, only scar tissue was notice-
able (Fig 1, after).
Vemurafenib is an anti-BRAF targeted therapy
approved for the treatment of metastatic unresect-
able melanoma with V600 mutations; sensitivity to
this molecule was recently demonstrated for BRAF
mutated non-LCH (ie, CD1- negative Erdheim-
Chester disease).2 Here we report a major clinical
response to vemurafenib for refractory, widespread,
skin-limited, pure LCH carrying the BRAF V600E-ND license.
Fig 1. Langerhans cell histiocytosis and vemurafenib response. Inframammary folds
(upper images) and left groin area (lower images) before and after a 6-months period of
vemurafenib treatment.
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of LCH, it would also be important to evaluate
whether vemurafenib can diffuse and be effective
in bones and brain.
The rapid response and remarkable efficacy of
vemurafenib in this case should encourage prac-
titioners to perform systematic BRAF gene muta-
tion testing for LCH patients. These results also
suggest that this strategy could become a new
gold standard first-line treatment for BRAF V600E
LCH after further validation in prospective multi-
center trials.
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Fig 2. Histologic and immunohistologic pictures of Langerhans cell histiocytosis. A, Histolog-
ically, tumor cells were medium-sized, with grooved or indented nuclei and abundant
eosinophilic cytoplasms. Moderate cellular pleomorphism was also a feature. Mitoses were not
exceptional, with absence of overtly atypical forms. B, Low-power view of the biopsy specimen
before treatment. C, Tumor cells were uniformly stained by the CD1a antibody, which also
highlighted epidermotropic tumor cells.D, After 3 weeks of vemurafenib treatment, the dermal
infiltrate had entirely disappeared, being replaced by mixed inflammatory cells. E, After
treatment, immunostaining for CD1a was restricted to skin-resident Langerhans cells. (A, B, and
D, Hematoxylin-eosin stain; original magnifications: A, 340; B, 32.5; D, 32.5. C and E, SABC;
original magnifications: C, 310; E, 35.)
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Extensive scleredema adultorum with loss of
eccrine glands
To the Editor: Scleredema adultorum is a disease
characterized by woody induration of the skin,1 in
which the skin appendages are usually preserved.
Here, we report a case of scleredema adultorumwith
loss of eccrine glands leading to frequent heat
strokes.
A 50-year-old Taiwanese woman visited us for
hardened and thickened skin extending from the
nape to the lower aspect of her back over the past 5years. Her back became anhidrotic and the front of
her trunk seemed hyperhidrotic. In the meantime,
she became progressively intolerant to heat and
experienced several episodes of heat strokes. She
refrained from outdoor activities to avoid heat
strokes. She had a 20-year history of type 2 diabetes
mellitus under insulin treatment over the past 10
years. She denied previous radiotherapy, topical
medications, toxin exposure, or family history of
similar skin changes. Neither photosensitivity nor
arthritis was present.
Examination revealed the skin from her nape to
the lower aspect of her back was hardened and
thickened, except the side aspects. The overlying
skin was slightly erythematous with preservation of
the hair follicles. Starch-iodine test showed the
lesional skin was anhidrotic (Fig 1). Her blood tests
were negative for antinuclear antibody, anti-Scl-70
antibody, and rheumatoid factor and pulmonary
function test result was within normal limits.
Fasting glucose level was 234 mg/dL and hemoglo-
bin A1c (HbA1c) was 9.6%.
